Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

2 recruiting4 with results

Enrollment Performance

Analytics

Phase 1

3(42.9%)

Phase 2

2(28.6%)

Phase 3

2(28.6%)

7Total

Phase 1(3)

Phase 2(2)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07284784Phase 2Recruiting

A Study of Buntanetap in Participants With PD

Role: lead

NCT06709014Phase 3Recruiting

A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Role: lead

NCT05686044Phase 2Completed

A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

Role: lead

NCT05357989Phase 3Completed

A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Role: lead

NCT02925650Phase 1Completed

Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease

Role: lead

NCT04524351Phase 1Completed

Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients

Role: lead

NCT01072812Phase 1Terminated

Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment

Role: lead

All 7 trials loaded